Evidence map›Paper›PMID 32988214›Full record

ArticleAIDS research and human retroviruses2020

The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.

Kate M Guthrie, Joseph L Fava, Sara E Vargas, Rochelle K Rosen, Julia G Shaw, Erna M Kojic, Anthony S Ham, Lisa C Rohan, David Katz, Anacecilia Panameño and 4 more

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Kate M GuthrieCenter for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
Joseph L FavaCenter for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
Sara E VargasCenter for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
Rochelle K RosenCenter for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
Julia G ShawCenter for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
Erna M KojicDivision of Infectious Disease, Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Anthony S HamImQuest BioSciences, Inc., Frederick, Maryland, USA.
Lisa C RohanMagee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
David KatzDepartment of Bioengineering, Duke University, Durham, North Carolina, USA.
Anacecilia PanameñoCenter for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
Christopher ColleranCenter for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
David F FriendCONRAD, Arlington, Virginia, USA.
Karen W BuckheitImQuest BioSciences, Inc., Frederick, Maryland, USA.
Robert W BuckheitImQuest BioSciences, Inc., Frederick, Maryland, USA.
Brown University · USContraception Research and Development · USDuke University · USMagee-Womens Research Institute · US

Funding

Pharmaceutical and Regulatory CoreU19AI082639 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI ROHAN, LISA CENCIA · 2010 to 2014
$13.0M
Rational Development of Combination Microbicide TherapiesR33AI076967 · NIAID · IMQUEST BIOSCIENCES · PI BUCKHEIT, ROBERT WALTER · 2008 to 2010
$1.4M
Advancing Reproductive Health: Qualitative Methods & Interdisciplinary MentorshipK24HD062645 · NICHD · MIRIAM HOSPITAL · PI GUTHRIE, KATE M · 2012 to 2016
$689k
NIAID NIH HHS R33 AI076967NIAID NIH HHS U19 AI082639NICHD NIH HHS K24 HD062645
6 · The paper itself

Abstract

Users' sensory perceptions and experiences (USPEs; perceptibility) of drug formulations can critically impact product adoption and adherence, especially when products rely on appropriate user behaviors (timing of administration, dosing measurement) for effectiveness. The use of topical gel formulations for effective antihuman immunodeficiency virus/sexually transmitted infection (HIV/STI) vaginal microbicides has been associated with messiness and other use-associated challenges, resulting in low adherence. Nonetheless, such formulations remain attractive due to good pharmacokinetics and resulting pharmacodynamics through their volume and surface contact for drug delivery into luminal fluids and mucosa. Consequently, advocates and scientists continue to pursue topical forms [semisolid (e.g., gel, suppository); solid (e.g., film)] to deliver select drugs and offer user choice in HIV/STI prevention. The current data build on previously validated USPE scales evaluating perceptibility of gels with various biophysical/rheological properties. Specifically, increased formulation parameter space adds a new set of properties inherent in quick-dissolving film. We compared film, a product adding no discernable volume to the vaginal environment, to 2 and 3.5 mL hydroxyethyl cellulose gel to consider the impact of volume on user experience. We also examined the USPE scales for evaluation of male sexual partners' experiences. The original USPE scales functioned as expected. Additionally, six new USPE scales were identified in this enhanced parameter space. Significant differences were noted between USPEs in pairwise comparisons, with largest differences between film and high-volume gel. Product developers and behavioral scientists can use these scales to design products, optimizing user experience and maximizing adherence and delivery of efficacious anti-HIV/STI pharmaceuticals. They can be extended to evaluation of additional formulations, devices, and compartments, as well as single- and multipurpose pharmaceuticals. In broader contexts, USPEs could be of value in evaluating formulations and devices to prevent/treat other diseases (e.g., ophthalmologic, dermatologic). Steadfast attention should be given to patient experience, and, where applicable, experiences of partners and/or caregivers.

Indexed as

HIV InfectionsSexually Transmitted DiseasesAdministration, IntravaginalFemaleHeterosexualityHumansMalePerceptionReproducibility of ResultsSensationVaginaVaginal Creams, Foams, and JelliesVaginal Creams, Foams, and Jelliesadherenceformulation designHIV preventionmicrobicidesuser experience

Identifiers

PMID32988214
PMCPMC7703150
OpenAlexW3091512594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.